Vera Therapeutics, a biotechnology company developing treatments for immunological diseases, reported a first-quarter net loss of $121 million, or $1.69 per share, compared to a $51.7 million loss in the same period last year. The FDA granted priority review to Vera's biologics licence application for atacicept, an investigational treatment for IgA Nephropathy in adults, with a target decision date of 7 July 2026. The company is preparing for a mid-2026 US commercial launch pending regulatory approval. Vera reported $596.8 million in cash, cash equivalents and marketable securities as of 31 March 2026, which it believes will fund operations beyond potential approval and commercial launch. The company anticipates initial results from its PIONEER Phase 2 trial in the second quarter of 2026.

Vera Therapeutics to participate in the Bank of America Securities 2026 Health Care Conference. GlobeNewswire | Vera Therapeutics Today at 4:30am PDT BRISBANE, Calif., May 04, 2026 (GLOBE NEWSWIRE) - Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will present at the Bank of America Securities 2026 Health Care Conference, which is taking place in Las Vegas, NV from May 12-14, 2026. The management team will also participate in one-on-one investor meetings. Presentation Details: Date: Wednesday, May 13, 2026 Time: 4:20 PM PDT Webcast: https://bofa.veracast.com/webcasts/bofa/healthcare2026/24Ty86.cfm A replay of the event will be available for 90 days and can be accessed by visiting the "Investor Calendar" section of the Vera Therapeutics website. About Vera Therapeutics Vera Therapeutics is a biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics' mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics' lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also evaluating the development of MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109, and MAU868. For more information, please visit www.veratx.com. Forward-looking Statements Statements contained in this press release regarding matters, events or results that may occur in the future are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, Vera Therapeutics' plans, commitments, aspirations and goals related to its product candidates. Words such as "anticipate," "believe," "expect," "may," "plan," "potential," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera Therapeutics' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera Therapeutics' business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera Therapeutics' filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Vera Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. This is a paid placement. For further inquiries, please contact GlobeNewswire directly.

Vera Therapeutics has granted inducement awards to Jane Wright-Mitchell, its new Chief Legal Officer, consisting of non-qualified stock options to purchase 56,850 shares and restricted stock units underlying 42,403 shares of Class A common stock. The Compensation Committee approved the awards on 23 March 2026 under the company's 2024 Inducement Plan. The stock options have an exercise price of $40.73 per share and will vest over four years, with 25% vesting after the first anniversary and the remainder vesting monthly over 36 months. The RSU award will vest 25% annually over four years starting 20 May 2026. Vera Therapeutics is a late clinical-stage biotechnology company developing treatments for immunological diseases, with atacicept as its lead product candidate targeting autoimmune diseases including IgAN and lupus nephritis.